The EU legislature has finally reached an agreement on the text of the Corporate Sustainability Due Diligence Directive (CS3D) (see here our previous client alert). The CS3D profoundly affects the ways companies active in...more
On October 16, 2023, the Committee on International Trade (INTA) and the Committee on Internal Market and Consumer Protection (IMCO) of the European Parliament adopted their position (the Committee Position; see here and...more
On 23 February 2022, the European Commission (“Commission”) adopted a proposal for a Corporate Sustainability Due Diligence Directive (“Proposed Directive”) laying down new obligations for large companies to ensure that their...more
The object of this Alert is to highlight some practical implications of Brexit for the supply of pharmaceutical products and medical devices in the European Union (EU) and related action items which companies should be...more
4/6/2018
/ EU ,
EU Single Market ,
European Economic Area (EEA) ,
European Medicines Agency (EMA) ,
Free Trade Agreements ,
Marketing Authorization Application ,
Medical Devices ,
Pharmaceutical Industry ,
Supply Chain ,
UK ,
UK Brexit